Trial Profile
To investigate the association of T790M-mutant status and clinical outcomes after Osimertinib treatment in Chinese NSCLC patients harboring acquired EGFR T790M mutation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Oct 2018
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 09 Oct 2018 New trial record
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer